Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

This study reports that long-term use of finasteride does not affect bone mineral density in men with benign prostatic hyperplasia over a four-year period.

This study found that initiation of 5α-reductase inhibitors like finasteride is not associated with an increased risk of depression in veterans, suggesting depression may be linked to underlying health conditions instead.

Doxazosin and finasteride negatively affect sexual function in men with BPH.

This study evaluates finasteride's safety and efficacy for treating male chronic pelvic pain syndrome, but the abstract does not report any results.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

This editorial examines the use of multiple drugs for treating lower urinary tract symptoms due to benign prostatic hyperplasia but offers no new research findings.

This study found that depression, anxiety, and sleep disturbance were associated with male lower urinary tract symptoms, but these factors did not predict improvement after evaluation and treatment over time.

In this study, the authors observed that treatment patterns for new benign prostatic hyperplasia largely aligned with guidelines, but 5-α reductase inhibitors were used inappropriately based on prostate size as indicated by prostate specific antigen.

This study found that folliculin deficient renal cancer cells were more sensitive to irradiation due to increased autophagic cell death, suggesting a potentially enhanced therapeutic approach when combined with autophagy inducers like rapamycin.

In this study, patients with larger prostates were observed to have a higher prevalence of androgenetic alopecia.

This review discusses various treatments for benign prostatic hyperplasia, comparing medications like finasteride and terazosin, as well as surgical and placebo options, without presenting new clinical findings.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

This study concluded that dutasteride modestly reduces nocturia in men but does not improve sleep quality.

This study found that men aged 60 or older with postoperative urinary retention were more likely to undergo bladder outlet procedures within three years.

This article highlights various research studies in adult urology from the July 2013 issue of the Journal of Urology but does not report new research findings itself.

This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.

This study reported that seminal vesiculoscopy combined with transurethral resection of ejaculatory ducts and balloon dilation effectively resolved hematospermia and improved symptoms in a patient whose condition was unresponsive to medical treatments.

This study found that the 1 mg dose of finasteride was associated with a wide range of adverse effects, including sexual, psychological, and metabolic symptoms, in the FAERS data.

This study observed that many couples in North America undergo IUI or IVF for male infertility without specialized male factor evaluations, potentially overlooking reversible causes.

Finasteride daily doesn't affect sperm production or semen in young men.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

This study observed that discontinuation rates due to side effects were similar for penicillamine and tiopronin among cystinuria patients, and switching to the alternative agent was beneficial for half of those experiencing issues.

This article discusses the potential mechanism by which 5α-reductase inhibitors might offer protection against SARS-CoV-2, emphasizing possible roles of dehydroepiandrosterone and its impact on nitric oxide bioavailability, but reports no new experimental results.

This commentary discusses Post-Finasteride Syndrome as a challenge for clinicians and provides no new clinical results; the author focuses on the condition's manageability.

This letter references a previous systematic review and meta-analysis on how nocturia may impact mortality but does not present new findings itself.

This study found that men with depression, erectile dysfunction, and marijuana usage were more likely to be treated for lower urinary tract symptoms, while alcohol use was not significantly associated.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.